ACOD1 and neoplasm: Administration with SCH546738 reversed the effect of Irg1 deficiency on facilitating T cell chemotaxis and diminished the tumoricidal effect in vivo (Fig. 3, G and H), suggesting the potential role of IRG1 in limiting T cell trafficking into the tumor.